Drug General Information
Drug ID
D02ZKR
Former ID
DNC008301
Drug Name
BCX-3408
Synonyms
R-3421
Drug Type
Small molecular drug
Indication Discovery agent Phase 2 [522068]
Structure
Download
2D MOL

3D MOL

Formula
C12H16N4O3
Canonical SMILES
C1C(C(CN1CC2=CNC3=C2NC=NC3=O)O)CO
InChI
1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
InChIKey
AFNHHLILYQEHKK-BDAKNGLRSA-N
PubChem Compound ID
Target and Pathway
Target(s) Purine nucleoside phosphorylase Target Info Inhibitor [529290]
BioCyc Pathway Arsenate detoxification I (glutaredoxin)
Purine nucleotides degradation
Urate biosynthesis/inosine 5'-phosphate degradation
Purine deoxyribonucleosides degradation
Purine ribonucleosides degradation to ribose-1-phosphate
Guanosine nucleotides degradation
Adenosine nucleotides degradation
Superpathway of purine nucleotide salvage
Adenine and adenosine salvage III
Guanine and guanosine salvage
KEGG Pathway Purine metabolism
Pyrimidine metabolism
Nicotinate and nicotinamide metabolism
Metabolic pathways
NetPath Pathway TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Adenine and hypoxanthine salvage pathway
Xanthine and guanine salvage pathway
PathWhiz Pathway Purine Metabolism
Nicotinate and Nicotinamide Metabolism
Reactome Purine salvage
Purine catabolism
WikiPathways miR-targeted genes in squamous cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in leukocytes - TarBase
miR-targeted genes in epithelium - TarBase
Metabolism of nucleotides
References
Ref 522068ClinicalTrials.gov (NCT00504270) A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.. U.S. National Institutes of Health.
Ref 529290J Med Chem. 2008 Feb 28;51(4):948-56. Epub 2008 Feb 6.Azetidine based transition state analogue inhibitors of N-ribosyl hydrolases and phosphorylases.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.